Preferred Label : Non-Small Cell Lung Cancer Pathway;
NCIt synonyms : NSCLC Pathway;
NCIt related terms : Non-small cell lung cancer;
Alternative definition : KEGG: Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer
and represents a heterogeneous group of cancers, consisting mainly of squamous cell
(SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC
include activation of oncogenes, such as K-RAS and c-erbB-2, and inactivation of tumor
suppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within
the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits
growth signals to the nucleus. Overexpression of c-erbB-2 or EGFR leads to a proliferative
advantage. Inactivating mutation of p53 can lead to more rapid proliferation and reduced
apoptosis. The protein encoded by the p16INK4a gene inhibits formation of CDK-cyclin-D
complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is
a common feature of NSCLC RAR-beta is a nuclear receptor that bears vitamin-A-dependent
transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS
effector. Therefore, loss of RASSF1A might shift the balance of RAS activity towards
a growth-promoting effect.;
KEGG ID : hsa05223;
Origin ID : C91445;
UMLS CUI : C2984258;
Automatic exact mappings (from CISMeF team)
See also inter- (CISMeF)
Semantic type(s)
has_gene_product_element
pathway_has_gene_element